Associated Banc Corp Cuts Stake in AbbVie Inc. $ABBV

Associated Banc Corp trimmed its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 40,775 shares of the company’s stock after selling 2,967 shares during the quarter. Associated Banc Corp’s holdings in AbbVie were worth $9,317,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ABBV. Brighton Jones LLC grew its position in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. boosted its holdings in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the last quarter. Ieq Capital LLC boosted its holdings in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after acquiring an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its holdings in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after acquiring an additional 612,702 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Get AbbVie alerts:

Insider Buying and Selling

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ABBV shares. UBS Group dropped their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. Piper Sandler raised their price target on shares of AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 17th. Finally, Barclays started coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $253.43.

Check Out Our Latest Stock Report on ABBV

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

AbbVie Stock Up 0.7%

Shares of NYSE:ABBV opened at $216.02 on Friday. AbbVie Inc. has a twelve month low of $181.71 and a twelve month high of $244.81. The stock has a market capitalization of $381.65 billion, a PE ratio of 106.41, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32. The firm’s 50 day moving average price is $208.72 and its 200-day moving average price is $219.68.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the business earned $2.46 EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. Analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Articles

• Five stocks we like better than AbbVie
• SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
• CAVA Group’s Stock Looks Delicious After Strong Earnings
• Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
• Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.